A new trading day began on Friday, with Kairos Pharma Ltd (AMEX: KAPA) stock price up 5.88% from the previous day of trading, before settling in for the closing price of $1.02. KAPA’s price has ranged from $0.40 to $4.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -23.37% over the past five years. Meanwhile, its annual earnings per share averaged 7.25%. With a float of $7.12 million, this company’s outstanding shares have now reached $15.83 million.
Let’s look at the performance matrix of the company that is accounted for 4 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Kairos Pharma Ltd (KAPA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Kairos Pharma Ltd is 57.73%, while institutional ownership is 9.36%. The most recent insider transaction that took place on Nov 25 ’24, was worth 318. In this transaction VP of Research and Development of this company bought 200 shares at a rate of $1.59, taking the stock ownership to the 133,057 shares. Before that another transaction happened on Nov 22 ’24, when Company’s Chief Financial Officer bought 2,500 for $1.50, making the entire transaction worth $3,750. This insider now owns 60,796 shares in total.
Kairos Pharma Ltd (KAPA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -24.45% during the next five years compared to -23.37% drop over the previous five years of trading.
Kairos Pharma Ltd (AMEX: KAPA) Trading Performance Indicators
Here are Kairos Pharma Ltd’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.25, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.34 in one year’s time.
Technical Analysis of Kairos Pharma Ltd (KAPA)
Kairos Pharma Ltd (AMEX: KAPA) saw its 5-day average volume 51.98 million, a positive change from its year-to-date volume of 3.4 million. As of the previous 9 days, the stock’s Stochastic %D was 36.00%.
During the past 100 days, Kairos Pharma Ltd’s (KAPA) raw stochastic average was set at 47.89%, which indicates a significant increase from 37.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1453 in the past 14 days, which was higher than the 0.1037 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6555, while its 200-day Moving Average is $1.1611. Nevertheless, the first resistance level for the watch stands at $1.2363 in the near term. At $1.3927, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.5553. If the price goes on to break the first support level at $0.9173, it is likely to go to the next support level at $0.7547. Assuming the price breaks the second support level, the third support level stands at $0.5983.
Kairos Pharma Ltd (AMEX: KAPA) Key Stats
With a market capitalization of 18.20 million, the company has a total of 16,849K Shares Outstanding. Currently, annual sales are 0 K while annual income is -2,600 K. The company’s previous quarter sales were 0 K while its latest quarter income was -1,260 K.
